Based on data synthesized in Cochrane reviews, some MIGS may afford patients with glaucoma greater drop-free disease control than cataract surgery alone. Among the products currently available, randomized clinical trial data associate the Hydrus with greater drop-free glaucoma control and IOP lowering than the iStent; however, these effect sizes were small.
No takes yet. Share an insight, caveat, or question.
Bicket et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: